Paratek Pharmaceuticals (FRA:N4CN) Stock Based Compensation : €10.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Stock Based Compensation?

Paratek Pharmaceuticals's Stock Based Compensation for the three months ended in Jun. 2023 was €2.1 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was €10.0 Mil.

Paratek Pharmaceuticals Stock Based Compensation Historical Data

The historical data trend for Paratek Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Stock Based Compensation Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Stock Based Compensation

Get a 7-Day Free Trial

22.41

12.87

8.43

12.69

11.63

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Stock Based Compensation	Get a 7-Day Free Trial															3.68	4.02	1.88	2.01	2.06

Paratek Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.0 Mil.

Paratek Pharmaceuticals Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines